Strategies for the development of novel Taxol-like agents.

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Taxol, the first microtubule stabilizer identified, is one of the most important new anticancer drugs to be brought to the clinic in the past 20 yr. The clinical success of TaxolTM led to the development of a second-generation taxane, docetaxel (Taxotere), and multiple third-generation taxane derivatives are under development. Non-taxane microtubule-stabilizers of diverse chemical structures, including the epothilones and discodermolide, show promising preclinical activities and several epothilones are progressing through clinical trials. One important advantage of the new stabilizers is their ability to circumvent drug resistance mechanisms. The clinical development of these new classes of agents suggests that microtubule stabilizers will continue to be important drugs for the treatment of cancer. This chapter provides a brief history of Taxol and the discovery and development status of other classes of microtubule stabilizers. Although all microtubule-stabilizers share similar mechanisms of action, interesting subtle differences among the stabilizers are being detected. This chapter also provides some strategies for identifying the differences among microtubule stabilizers that may help prioritize them for development and clinical use.

Original languageEnglish (US)
Pages (from-to)289-302
Number of pages14
JournalMethods in molecular medicine
Volume137
StatePublished - 2007
Externally publishedYes

Fingerprint

Paclitaxel
Microtubules
docetaxel
Epothilones
Drug Resistance
Pharmaceutical Preparations
Clinical Trials
Neoplasms

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Strategies for the development of novel Taxol-like agents. / Mooberry, Susan L.

In: Methods in molecular medicine, Vol. 137, 2007, p. 289-302.

Research output: Contribution to journalArticle

@article{4917e2068a8b4a749b08504aaa4d3a94,
title = "Strategies for the development of novel Taxol-like agents.",
abstract = "Taxol, the first microtubule stabilizer identified, is one of the most important new anticancer drugs to be brought to the clinic in the past 20 yr. The clinical success of TaxolTM led to the development of a second-generation taxane, docetaxel (Taxotere), and multiple third-generation taxane derivatives are under development. Non-taxane microtubule-stabilizers of diverse chemical structures, including the epothilones and discodermolide, show promising preclinical activities and several epothilones are progressing through clinical trials. One important advantage of the new stabilizers is their ability to circumvent drug resistance mechanisms. The clinical development of these new classes of agents suggests that microtubule stabilizers will continue to be important drugs for the treatment of cancer. This chapter provides a brief history of Taxol and the discovery and development status of other classes of microtubule stabilizers. Although all microtubule-stabilizers share similar mechanisms of action, interesting subtle differences among the stabilizers are being detected. This chapter also provides some strategies for identifying the differences among microtubule stabilizers that may help prioritize them for development and clinical use.",
author = "Mooberry, {Susan L}",
year = "2007",
language = "English (US)",
volume = "137",
pages = "289--302",
journal = "Methods in molecular medicine",
issn = "1543-1894",
publisher = "Humana Press",

}

TY - JOUR

T1 - Strategies for the development of novel Taxol-like agents.

AU - Mooberry, Susan L

PY - 2007

Y1 - 2007

N2 - Taxol, the first microtubule stabilizer identified, is one of the most important new anticancer drugs to be brought to the clinic in the past 20 yr. The clinical success of TaxolTM led to the development of a second-generation taxane, docetaxel (Taxotere), and multiple third-generation taxane derivatives are under development. Non-taxane microtubule-stabilizers of diverse chemical structures, including the epothilones and discodermolide, show promising preclinical activities and several epothilones are progressing through clinical trials. One important advantage of the new stabilizers is their ability to circumvent drug resistance mechanisms. The clinical development of these new classes of agents suggests that microtubule stabilizers will continue to be important drugs for the treatment of cancer. This chapter provides a brief history of Taxol and the discovery and development status of other classes of microtubule stabilizers. Although all microtubule-stabilizers share similar mechanisms of action, interesting subtle differences among the stabilizers are being detected. This chapter also provides some strategies for identifying the differences among microtubule stabilizers that may help prioritize them for development and clinical use.

AB - Taxol, the first microtubule stabilizer identified, is one of the most important new anticancer drugs to be brought to the clinic in the past 20 yr. The clinical success of TaxolTM led to the development of a second-generation taxane, docetaxel (Taxotere), and multiple third-generation taxane derivatives are under development. Non-taxane microtubule-stabilizers of diverse chemical structures, including the epothilones and discodermolide, show promising preclinical activities and several epothilones are progressing through clinical trials. One important advantage of the new stabilizers is their ability to circumvent drug resistance mechanisms. The clinical development of these new classes of agents suggests that microtubule stabilizers will continue to be important drugs for the treatment of cancer. This chapter provides a brief history of Taxol and the discovery and development status of other classes of microtubule stabilizers. Although all microtubule-stabilizers share similar mechanisms of action, interesting subtle differences among the stabilizers are being detected. This chapter also provides some strategies for identifying the differences among microtubule stabilizers that may help prioritize them for development and clinical use.

UR - http://www.scopus.com/inward/record.url?scp=38449093510&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38449093510&partnerID=8YFLogxK

M3 - Article

C2 - 18085237

AN - SCOPUS:38449093510

VL - 137

SP - 289

EP - 302

JO - Methods in molecular medicine

JF - Methods in molecular medicine

SN - 1543-1894

ER -